Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22563396 | 0.91 | ABL1 (0.38) | ABL1BCRGFERKDM4ETRPV1 | |
| SCHEMBL21721929 | 0.87 | CHEK2 (0.42) | ABL1BCRGFERKDM4ETRPV1 | |
| SCHEMBL21125955 | 0.87 | ABL1 (0.45) | ABL1BCRGFERKDM4ETRPV1 | |
| SCHEMBL19933690 | 0.86 | NPC1 (0.43) | ABL1BCRKDM4ETRPV1KMT2A | |
| SCHEMBL18573166 | 0.86 | ABL1 (0.51) | ABL1BCRKDM4ETRPV1KMT2A | |
| SCHEMBL21721909 | 0.84 | ABL1 (0.43) | ABL1BCRKDM4ETRPV1KMT2A | |
| SCHEMBL19933655 | 0.84 | ABL1 (0.43) | ABL1BCRGFERKDM4ETRPV1 | |
| SCHEMBL19933610 | 0.83 | ABL1 (0.46) | ABL1BCRKDM4ETRPV1KMT2A | |
| SCHEMBL23018780 | 0.82 | NPC1 (0.42) | ABL1BCRKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL19933702 | 0.81 | ABL1 (0.42) | ABL1BCRGFERKDM4ETRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136343-B2 | Binuclear metal complexes for use as emitters in organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| EP-3515925-B1 | BINUCLEAR METAL COMPLEXES FOR USE AS EMITTERS IN ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2020-10-21 | — | — | EP | disclosed |
| US-20190292210-A1 | BINUCLEAR METAL COMPLEXES FOR USE AS EMITTERS IN ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292210-A1 | BINUCLEAR METAL COMPLEXES FOR USE AS EMITTERS IN ORGANIC ELECTROLUMINESCENT DEVICES | AP2M1, MCU, AP3M1 | ABL1 3557/4885BCR 3642/4885GFER 2749/4885 |
| US-11136343-B2 | Binuclear metal complexes for use as emitters in organic electroluminescent devices | AP2M1, MCU, AP3M1 | ABL1 3557/4885BCR 3642/4885GFER 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.